Daanbiotpx

DAAN Biotherapeutics (다안바이오테라퓨틱스) is a Korean immuno-oncology company developing T-cell-directed cancer therapies. Its platforms center on the precise redirection and activation of T cells against tumors, and include TCR-T cell therapies, TCR-mimic T-cell engagers, and conditionally activated T-cell engagers. The company frames these modalities as complementary approaches to challenges limiting current immunotherapies, including tumor heterogeneity, off-tumor toxicity, insufficient tumor selectivity, and T-cell dysfunction in the tumor microenvironment.

The TCR-T cell therapy platform is designed to recognize intracellular tumor-specific antigens presented by peptide–HLA complexes, extending the addressable target space beyond cell-surface antigens. The TCR-mimic T-cell engager platform is positioned as an off-the-shelf approach that couples antibody druggability with TCR-like specificity for cancer-associated peptide–MHC complexes. The conditionally activated T-cell engagers are engineered to remain inactive in normal tissue and become selectively active within the tumor microenvironment in order to limit systemic toxicity. According to its venture investor FuturePlay, the company's cell therapy and antibody programs based on T-cell receptors are aimed at unmet need in lung cancer treatment.

Founding story

According to press coverage cited by FuturePlay, the company was founded by a physician known for lung cancer treatment, and its programs target unmet need in lung cancer.

Traction

Reported milestones include a Series A round of KRW 23 billion announced in January 2024, transfer of ADC antibody technology to LigaChem Bio in February 2025, a TCR therapeutics research and development agreement with Proteina in October 2024, partnership activity with Acrobiosystems in August 2025, ADC drug development work with Trioar reported in November 2025, and selection for a 2025 national program.